Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/44

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/207742NANOPARTICLES FOR USE IN PHOTODYNAMIC THERAPIES AND METHODS OF MAKING, EVALUATING AND USING THE SAME
WO 14.10.2021
Int.Class A61K 31/498
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
498Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
Appl.No PCT/US2021/026923 Applicant MI2 HOLDINGS LLC Inventor HOPKINS, Andrew
A nanocomposition for use in treating a pathogen condition using phthalocyanine dye, such as IR700. A nanocomposition having IR700, an 8PEG nanoparticle and a pathogen targeting peptide. Administering a product comprising IR700 to a patient, whereby the IR700 is delivered to pathogen tissue, and found in only pathogen tissue; and administering light to activate the IR700, thereby producing an ROS.
2.WO/2021/202929RAPID MULTIPLEXED SEROLOGICAL TEST
WO 07.10.2021
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No PCT/US2021/025456 Applicant GENALYTE, INC. Inventor GUNN, Lawrence, Cary, III
Disclosed herein are methods of performing multiplexed serological immunoassays to detect multiple antigens in parallel to determine if a patient has an infection or an immune disorder. Use of multiple antigens in parallel increases specificity and/or sensitivity towards assaying the infection or immune disorder. The infection may be a viral infection such as a SARS-CoV-2 viral infection, a variant of a SARS-CoV-2 viral infection, or a non-SARS-CoV-2 coronavirus infection. Also disclosed herein are methods of performing the multiplexed serological immunoassays on an optical ring resonator substrate. Also disclosed herein are methods of detecting antibodies specific for an antigen that belong to more than one immunoglobulin type.
3.WO/2021/163035ANTI-THYMOCYTE GLOBULIN
WO 19.08.2021
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/US2021/017218 Applicant SAB, LLC. Inventor SULLIVAN, Eddie J.
Provided are human anti-thymocyte globulin (ATG) products, and methods of making and using the same. In particular, the disclosure provides an ungulate-derived polyclonal immunoglobulin, comprising a population of fully human or substantially human immunoglobulins. The population of fully human or substantially human immunoglobulins specifically binds human thymocytes, T cells, B cells, and/or monocytes. Such compositions may be made by immunization of transgenic animals having a human Ig locus with human thymocyte. This method generates polyclonal immunoglobulin with yield, purity, and antigen specificity that enable use of this product in medical applications.
4.113121680一种抗H5亚型禽流感纳米抗体蛋白及其编码基因与应用
CN 16.07.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 202110390340.X Applicant 华南农业大学 Inventor 廖明
本发明属于生物药物技术领域,具体涉及一种抗H5亚型禽流感纳米抗体蛋白及其编码基因与应用。所述的抗H5亚型禽流感病毒纳米抗体蛋白的氨基酸序列如SEQ ID NO.1所示。该纳米抗体蛋白特异性针对甲型H5亚型禽流感病毒可以解决现有H5亚型禽流感诊断试剂研发过程中抗体亲和力低、生产过程中纯度低、检测过程中灵敏度低的问题。本发明进一步将抗H5亚型禽流感病毒纳米抗体蛋白在大肠杆菌体内和麦芽糖结合蛋白标签融合表达,可实现快速检测抗原,并应用于甲型H5亚型禽流感快速检测试剂盒的开发,且该融合蛋白可用于防治甲型H5亚型禽流感产品的开发。
5.WO/2021/138380VIRUS-LIKE PARTICLE BINDING AGENTS, RELATED COMPOSITIONS, AND RELATED METHODS
WO 08.07.2021
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No PCT/US2020/067394 Applicant UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. Inventor GHIM, Shin-je
Some embodiments of the invention include virus-like particle (VLP) binding agents, and related polynucleotides, cells, methods of making, and compositions. Other embodiments of the invention include methods of detecting VLPs, parvovirus, erythrovirus or parvovirus B19 using a VLP binding agent and diagnostic methods for parvovirus, erythrovirus or parvovirus B19. Further embodiments include methods for administering VLP binding agents to an animal. Other embodiments include treating parvovirus, erythrovirus or parvovirus B19 infections and other diseases. Additional embodiments of the invention are also discussed.
6.113018433Immune drug and application thereof in tumor immunotherapy
CN 25.06.2021
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 202110263141.2 Applicant HUNAN UNIVERSITY Inventor NIE ZHOU
The invention firstly provides an immune drug, the immune drug is a bispecific immune drug containing a specific binding protein and a nucleic acid aptamer, the specific binding protein and the nucleic acid aptamer are directly or indirectly connected, the specific binding protein is of a protein structure, and the nucleic acid aptamer is of a nucleic acid structure; the specific binding protein is used for being specifically bound with an immune cell receptor or a target cell receptor, and the corresponding nucleic acid aptamer is used for being specifically bound with the target cell receptor or the immune cell receptor. The invention also provides an application of the immune drug in tumor immunotherapy. According to the invention, the type of immunotherapy drugs is broadened, and the current bispecific antibody is evolved into a chimeric form in which DNA participates. The nucleic acid aptamer is used as a target cell recognition element, targeting of multiple types of tumor cells is achieved by means of the advantages that the nucleic acid aptamer is wide in targeting range and can be assembled into a nano structure in a programmed mode, and the affinity and specificity of combination of the nucleic acid aptamer and the tumor cells are improved.
7.113018432Preparation method of immune drug
CN 25.06.2021
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 202110263132.3 Applicant HUNAN UNIVERSITY Inventor NIE ZHOU
The invention provides a preparation method of an immune drug. The preparation method comprises the following steps: preparing a fusion protein containing a specific binding protein and a covalent connecting protein; preparing a nucleic acid structure containing the nucleic acid aptamer and covalently linked DNA; incubating the obtained fusion protein and the nucleic acid structure together, so the covalent connection protein and the covalent connection DNA in the fusion protein and the nucleic acid structure are covalently combined to obtain the immune drug. According to the invention, the type of immunotherapy drugs is broadened, and the current protein bispecific antibody is evolved into a chimeric form in which DNA participates. The preparation method provided by the invention overcomes the defect that the traditional bispecific antibody must be subjected to genetic engineering, shortens the synthesis and preparation time of the immune drug, and reduces the production cost. The nucleic acid aptamer is used as a target cell recognition element, and by virtue of the advantage of multivalent combination of the nucleic acid aptamer, tumor recognition types are diversified, the affinity and specificity of combination with tumor cells are improved, and the recognition range is expanded.
8.WO/2021/113974HUMANIZED ANTI-GLYCOPROTEIN IB ALPHA (GPIBALPHA) ANTIBODIES
WO 17.06.2021
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CA2020/051699 Applicant CCOA THERAPEUTICS INC. Inventor NI, Heyu
Multivalent anti-platelet glycoprotein l(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein l(b)alpha and lacking a Fc portion, therefore do not interact with Fc receptor. The humanized antibodies are capable of preventing platelet activation and aggregation, and reducing thrombus size / growth and prevent vessel occlusion. They can be also very useful to decrease platelet-tumor cell interaction and decrease tumor metastasis. At therapeutic doses, the humanized antibodies lack the ability to induce platelet activation, induce thrombocytopenia; and/or prolong bleeding time.
9.112891554Anti-tumor PD-L1 monoclonal antibody targeting drug-loaded polymer as well as preparation method and application thereof
CN 04.06.2021
Int.Class A61K 47/60
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Appl.No 202110315760.1 Applicant THE FIRST PEOPLE'S HOSPITAL OF LIANYUNGANG Inventor WU FENGLEI
The invention discloses an anti-tumor PD-L1 monoclonal antibody targeting drug-loaded polymer and a preparation method and application thereof. The structural formula of the anti-tumor PD-L1 monoclonal antibody targeting drug-loaded polymer is shown in formula (I), and the anti-tumor PD-L1 monoclonal antibody targeting drug-loaded polymer is prepared by the following steps: polyethylene glycol 2000 with one protected end amino and two aminated ends and caprolactone are subjected to ring-opening polymerization reaction to generate polyethylene glycol-polycaprolactone, and then, amino at the tail end of polyethylene glycol-polycaprolactone and carboxyl at the tail end of the PD-L1 monoclonal antibody are subjected to amidation reaction. Compared with the prior art, the tumor PD-L1 monoclonal antibody targeting drug-loaded polymer has good targeting property and small toxic and side effects, is prepared by a ring-opening polymerization method, can also be used for obtaining drug-loaded polymer nanoparticles by a nanoprecipitation method, and has the advantages of simple process, low cost, high yield and few side reactions.
10.WO/2021/096951LIPOSOME COMPOSITIONS AND METHODS OF TREATMENT TARGETED TO TUMOR ENDOTHELIUM
WO 20.05.2021
Int.Class A61K 9/127
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
Appl.No PCT/US2020/060004 Applicant WASHINGTON UNIVERSITY Inventor AZAB, Abdel Kareem
Compositions and methods of treatment for multiple myeloma (MM) are disclosed that include a liposome with a lipid bilayer shell enclosing a fluid-filled center, a targeting moiety coupled to the outer surface of the shell, a treatment compound disposed within the lipid bilayer shell or within the fluid-filled center, and an efficacy-enhancing compound disposed within the lipid bilayer shell or within the fluid-filled center. In some embodiments, the targeting moiety is PSGL-1, the proteasome-inhibiting compound is bortezomib, and the BMME-disrupting agent is a CXCR4 inhibitor or ROCK inhibitor.